High dose chemotherapy with haematopoietic rescue in breast cancer

Hematology and Cell Therapy

Volumn 41, Issue 2, 1999, Pages 58-65

  Bezwoda, W R ^a  

^a UNIVERSITY OF THE WITWATERSRAND MEDICAL SCHOOL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; VINCRISTINE;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; PATIENT SELECTION; REMISSION; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

EID: 0032951169     PISSN: 12693286     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00282-999-0058-y     Document Type: Conference Paper

References (25)

1. Antman K, Peters W P, Eden JP, et al (1985) Treatment of 58 patients on a phase I and II protocol using high dose combination alkylating agent preparation regimen with autologous marrow support. In Fortune JG Rhoads JE (Eds) Accomplishments in Cancer Research Philladelphia PA, JB Lippincott pp 152-165
2. Kennedy MJ, Beveredge RA, Rowley SD (1991) High dose chemotherapy with infusion of purged autologous bone marrow following dose-intensive induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst 83: 920-926
3. Huan S, Yau J, Wallerstein R, et al (1991) Characteristics of long term progression free survival after tandem high-dose cyclophosphamide, etoposide and cisplatin (CVP) for breast cancer patients (Absts). Pro Am Soc Clin Oncol 10: 115
4. Antman K, Ayash L, Elias AD, et al (1992) A phase II study of high dose cyclophosphamide thiotepa and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard dose therapy. J Clin Oncol 10: 102-110
5. Greenberg PAC, Hortobaygi GN, Smith TL, et al (1996) Long term follow up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14: 2197-2205
6. Falkson G, Holcroft C, Gelman RS, et al (1995) Ten year follow up study of pre-menopausal women with metastatic breast cancer. An Eastern Co-operative Oncology Group Study. J Clin Oncol 13: 1453-1458
7. Frassinetti GL, Zoli W, Tienghi A, et al (1996) Phase I/II study of sequential combination of paclitaxel and doxorubicin in the treatment of advanced breast cancer (ABC) Astr. Proc Am Soc Clin Oncol 15: 103
8. Rahman ZU, Frye DK, Buzdar AU, et al (1997) Impact of selection process on response rate and long term survival of potential high dose chemotherapy candidates treated with standard-dose doxorubicin containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol 15: 3131-3177
9. Garcia-Carbonero R, Hidalgo M, Paz-Ares L, et al (1997). Patient selection in high dose chemotherapy trials: Relevance in high-risk breast cancer. J Clin Oncol 15: 3178-3184
10. Crimp M, Goss PE, Prince M, et al (1996) Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and ten or more positive axillary lymph nodes. J Clin Oncol 14: 66-69
11. Skippe HE, Schabel FM Jnr, Wilcox WS (1964) Experimental evaluation of potential anti-cancer agents XIII on the criteria and kinetics associated with 'curability' of experimental leukemia. Cancer Chothe Rep. 35: 1-37
12. Schabel FM Jr, Griswold DP, Corbett TH, et al (1984) Increasing the therapeutic response rate to anti-cancer drugs by applying the basic principles of pharmacology. Cancer 50: 1160-1167.
13. Tannock IF, Boyd NF, de Boer G (1988) A randomised clinical trial of two dose levels of cyclophosphamide methotrexate and fluorouracil chemotherapy for metastatic breast cancer. A randomised trial. J Clin Oncol. 6: 1377-1381
14. Bastholt L, Dalmark M, Gjedde S, et al (1996) Dose response relationship of epirubicin in the treatment of post-menopausal patients with metastatic breast cancer in a randomised study of epirubicin at four different dose levels performed by the Danish Breast Cancer Co-operative Group. J Clin Oncol 14: 1146-1151
15. Hyriniuk WM, Levine MN (1986) Analysis of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 4: 1162-1170
16. Pu QQ, Bezwoda WR Induction of alkylator (melphalan) resistance in HL60 cells is accompanied by increased levels of topoisomerase II expression and function (In press)
17. Bezwoda WR, Dansey R, Seymour L (1995) High dose chemotherapy with haematopoietic rescue as primary treatment for metastatic breast cancer: a randomised trial. J Clin Oncol 13: 2483-2489
18. Bezwoda WR (1998) Primary high dose chemotherapy for metastatic breast cancer: update and analysis of prognostic factors (Absts). Proc Am Soc Clin Oncol 17: 445
19. Bezwoda WR (1997) In-vitro pruging of peripheral stem cell products by high dose CNVp: results from a randomised study comparing conventional dose chemotherapy (CNV) with double high dose CNVp chemotherapy. Proc Am Soc Clin Oncol 16: 404
20. Peters WP, Ross M, Vredenby JL, et al (1993) High dose chemotherapy and autologous bone marrow support on consolidation after standard dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11: 1132-1143
21. Ayash LJ, Elias A, Ibrahim J, et al (1998) High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast cancer. J Clin Oncol 16: 1000-1007
22. Rodenhuis S, Richel DJ, van der Wall E, et al (1998) A randomised trial of high-dose chemotherapy and haematopoietic progenitor cell support in operable breast cancer with extensive axillary lymph node involvement (Absts). Proc Am Soc Clin Oncol 17: 470
23. Bordeleau L, Bociek G, Bredersone C, et al (1998) Cost comparison of standard chemotherapy (CT) versus high-dose chemotherapy with autologous stem cell transplantation (HCACT) in metastatic breast cancer (MBC) (Absts). Proc Am Soc Clin Oncol 17: 415
24. Falkson G, Gellman RS, Pandya KT, et al (1998) Eastern cooperative oncology group randomised trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol 16: 1669-1676
25. Ueno NT, Rondon G, Mirza NQ, et al (1998) Allogeneic peripheral-blood progenitor cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 16: 986-993